JANX (Janux Therapeutics) Construction In Progress : $0.00 Mil (As of Sep. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Janux Therapeutics Construction In Progress?

Janux Therapeutics's annual construction in progress increased from Dec. 2021 ($0.14 Mil) to Dec. 2022 ($0.15 Mil) but then declined from Dec. 2022 ($0.15 Mil) to Dec. 2023 ($0.04 Mil).

Janux Therapeutics Construction In Progress Historical Data

The historical data trend for Janux Therapeutics's Construction In Progress can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Janux Therapeutics Construction In Progress Chart

Janux Therapeutics Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Construction In Progress

0.14

0.15

0.04

Janux Therapeutics Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Construction In Progress	Get a 7-Day Free Trial															0.34	0.04	-	-	-

Janux Therapeutics Construction In Progress Calculation

It records the cost of construction work, which is not yet completed (typically, applied to capital budget items). A construction in progress item is not depreciated until the asset is placed in service. Normally, upon completion, a construction in progress item is reclassified, and the reclassified asset is capitalized and depreciated.

Janux Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Janux Therapeutics Inc (NAS:JANX) » Definitions » Construction In Progress

Comparable Companies

Traded in Other Exchanges

N/A

Address

10955 Vista Sorrento Parkway, Suite 200, San Diego, CA, USA, 92130

Website

https://www.januxrx.com

Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing next-generation therapeutics based on proprietary tumor activated T Cell Engager platform technology to treat patients suffering from cancer.

Executives

David Alan Campbell	director, officer: Chief Executive Officer	C/O JANUX THERAPEUTICS, INC., 11099 N. TORREY PINES ROAD, SUITE 290, LA JOLLA CA 92037
Ra Capital Healthcare Fund Lp	director, 10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Avalon Ventures Xi, L.p.	10 percent owner	1134 KLINE STREET, LA JOLLA CA 92037
Andrew Hollman Meyer	officer: Chief Business Officer	C/O JANUX THERAPEUTICS, INC., 11099 N. TORREY PINES ROAD, SUITE 290, LA JOLLA CA 92037
Jay Lichter	director, 10 percent owner	C/O ARATANA THERAPEUTICS, INC., 11400 TOMAHAWK CREEK PARKWAY, SUITE 340, LEAWOOD KS 66211
Tighe Reardon	10 percent owner, officer: Acting Chief Financial Officer	C/O SYNTHORX, INC., 11099 NORTH TORREY PINES ROAD, SUITE 190, LA JOLLA CA 92037
Ra Capital Nexus Fund Ii, L.p.	director	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Charles M. Winter	officer: Chief Technical Officer	C/O JANUX THERAPEUTICS, INC., 10955 VISTA SORRENTO PARKWAY, SUITE 200, SAN DIEGO CA 92130
Winston Kung	director	C/O PMV PHARMACEUTICALS, INC., 8 CLARKE DRIVE, SUITE 3, CRANBURY NJ 08512
Byron Robinson	officer: Chief Strategy Officer	C/O JANUX THERAPEUTICS, INC., 11099 N. TORREY PINES ROAD, SUITE 290, LA JOLLA CA 92037
Orbimed Advisors Llc	director	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Peter A. Thompson	director	C/O ANTHERA PHARMACEUTICALS, INC., 25801 INDUSTRIAL BOULEVARD, SUITE B, HAYWARD CA 94545
Orbimed Capital Gp Viii Llc	director	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022-4629
Orbimed Genesis Gp Llc	director	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Orbimed Capital Gp Vii Llc	director	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022